Dr Lisa Licitra discusses the current and future treatment landscape in recurrent/metastatic head and neck cancer

Leading medical oncologist, Dr Lisa Licitra, Italy, discusses the impact of emerging immunotherapies, including nivolumab, in second-line treatment of recurrent/metastatic head and neck cancer following standard-of-care treatment, cetuximab and platinum-based therapy (EXTREME regimen).